Gastric Adenocarcinoma clinical trials

Study of paclitaxel for patients with taxane-resistant solid tumors

This trial tests paclitaxel given as tiny micelle particles for people whose cancer (pancreatic, bile duct, lung, stomach, esophagus, or breast) stopped responding to taxane chemotherapy or did not shrink. The goal is to see if this treatment can help when standard taxanes no longer work.

Chemoradiotherapy plus an immunotherapy for advanced gastric cancer

This trial studies a new immunotherapy drug (SHR-1701) combined with standard chemoradiotherapy for people with advanced stomach or esophagus cancer that cannot be surgically removed. The goal is to see if adding this immune treatment helps control the tumor better than standard treatments alone.

Oral Paclitaxel Plus Fruquintinib for Advanced Stomach Cancer

This trial tests a combination of two oral drugs (paclitaxel and fruquintinib) for advanced stomach cancer that has already been treated with one round of chemotherapy. The goal is to see if this combination helps control the cancer better than other standard second-line treatments.

New drug combo for HER2-positive stomach cancer

This trial tests a new immunotherapy called rilvegostomig combined with standard chemotherapy and a targeted therapy (trastuzumab deruxtecan) for people with advanced HER2-positive stomach or gastroesophageal junction cancer that has not been treated before.

Iparomlimab and chemotherapy vs chemotherapy alone for stomach cancer

This trial tests whether adding an immunotherapy drug (Iparomlimab and Tuvonralimab, combined as QL1706) to standard chemotherapy before surgery works better than chemotherapy alone for people with locally advanced stomach or gastroesophageal junction cancer that can be surgically removed.

HIPEC plus FLOT versus FLOT alone for gastric or GE junction cancer

This trial compares two treatment approaches after your stomach/GE junction cancer has been treated with chemotherapy before surgery: adding a special heated bath into the abdomen (HIPEC) plus continuing the usual surgery plan. It aims to see if adding HIPEC lowers cancer coming back and improves outcomes.

Drug combo before & after surgery for HER2+ stomach cancer

This trial tests a combination of three drugs (targeted therapy, immunotherapy, and chemotherapy) before and after surgery for locally advanced HER2-positive stomach cancer. It aims to see if this treatment can improve outcomes for patients whose cancer has not yet spread.

Hypoxia and metabolism in esophageal and stomach cancer

This trial looks at how low oxygen levels (hypoxia) affect the metabolism of esophageal and stomach cancers. It may help doctors understand why some cancers grow or resist treatment, possibly leading to better therapies.

Cabozantinib and immunotherapy for advanced stomach or bowel cancers

This early-phase study tests a combination of anti-cancer pills and immune-based treatment for people with advanced stomach, esophagus, colorectal, or liver cancer. It aims to shrink tumors and see how safe the treatment is, including whether biopsy testing can help guide future care.

Study of serplulimab with chemo before surgery for stomach cancer

This trial tests if adding serplulimab to standard chemotherapy before surgery can help shrink locally advanced stomach or gastroesophageal junction cancer. It aims to improve treatment outcomes for patients who are candidates for surgery.

A Randomized, Controlled, Open-Label, Multi-center Clinical Study Comparing the Efficacy of Close Follow-Up Versus Adjuvant Chemotherapy in Patients With Stage IB-IIA Gastric or Gastroesophageal Junction Adenocarcinoma Following Radical Surgery

LM-108 with Toripalimab vs Paclitaxel for advanced stomach cancer

This trial tests a new combination of two immunotherapy drugs (LM-108 and Toripalimab) against a standard chemotherapy drug (Paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that has a specific marker called CCR8. It may be an option if you have already tried a first-line therapy and your cancer has progressed or you had side effects from chemotherapy.

Adjuvant chemo plus immunotherapy for ctDNA-positive stomach cancer

This trial tests whether adding an anti-cancer immune treatment and another targeted drug to standard chemotherapy after surgery can lower the chance of cancer coming back. It is for people whose blood test (ctDNA) shows leftover cancer-related DNA after surgery.

Study of XNW27011 for advanced solid tumors that failed standard therapy

This trial tests an investigational drug called XNW27011 for people with advanced solid tumors that have not responded to standard therapies. It may be especially relevant for tumors that have a specific protein called CLDN18.2, but it is not required for the first part of the study.

Zanidatamab with pembrolizumab and chemo for HER2+ and PD-L1+ stomach cancer

This trial tests a new combination of targeted therapy (zanidatamab), immunotherapy (pembrolizumab), and chemotherapy for people with HER2-positive and PD-L1-positive advanced stomach or gastroesophageal cancer. It aims to see if this combination is more effective than current treatments.

Testing NEO212 for brain tumors and metastases

This trial tests a new drug called NEO212 for people with certain brain tumors (like astrocytoma or glioblastoma) or cancer that has spread to the brain from other parts of the body. The goal is to see if it is safe and if it can help shrink or control the tumors.

Test drug APL-101 for lung or other tumors with MET changes

This Phase 2 study tests APL-101 to shrink advanced cancers that have certain MET-related changes, including specific MET mutations, MET gene amplification, or MET fusions. It may help people whose tumors have run out of standard treatment options.

Combination therapy for advanced HER2-negative stomach cancer

This trial tests a combination of immunotherapy (candenizumab), a targeted therapy (lenvatinib), and chemotherapy (SOX regimen) for advanced HER2-negative stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if this combination is safe and works better than standard treatments.

New imaging test for different cancers using FAPI-PET

This trial is testing a new imaging method called FAPI-PET to see if it can help find and understand tumors better than standard scans. It is for people with newly diagnosed stomach/esophageal cancer, pancreatic cancer, or those with unclear symptoms or scan results.

Testing different doses of BI 765049 for advanced colorectal, stomach, or pancreatic cancer

This study tests a new drug (BI 765049) at different doses for people with advanced colorectal, stomach, or pancreatic cancer that cannot be removed by surgery or has spread. The goal is to find a safe and effective dose.

Comparing stomach reconstruction types after upper stomach cancer surgery

This study compares different ways to rebuild the digestive tract after removing the upper part of the stomach for cancer. It aims to find which method works best for eating and quality of life.

Predicting treatment response for advanced stomach cancer

This trial uses advanced testing to predict how well stomach cancer responds to chemotherapy combined with immunotherapy. It may help find the best treatment for advanced or metastatic stomach or gastroesophageal junction cancer that hasn't been treated yet.

PD-L1 antibody drug study for advanced lung and head/neck cancers

This Phase 1 trial tests a new experimental drug (PF-08046054/SGN-PDL1V) in people with advanced solid tumors that have not responded to standard treatment or can’t use it. It is designed to see how the drug works and how safe it is, with a focus on tumors that have PD-L1 seen on prior lab testing.

68Ga-BED003 PET scan for certain cancers

This trial tests a new PET imaging agent that targets a protein called FAP, which appears in many solid tumors. The goal is to see if this scan can better find and measure cancer in the body.